Managing Relapsed/Refractory Myeloma in the Era of New Agents for Treatment
This activity contains:
- CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator’s Guide (non-certified educational resources)
The goal of this activity is to provide nurses with an understanding of the latest clinical advances for the treatment and management of multiple myeloma.
The treatment armamentarium for multiple myeloma (MM) has expanded significantly in recent years, with 4 new therapies approved by the US Food and Drug Administration (FDA) in 2015 alone, making clinical and management decisions more difficult. Additionally, best practices and consensus guidelines, such as those from the National Comprehensive Cancer Network® (NCCN®) and International Myeloma Working Group (IMWG), are constantly evolving as new data are published.
This activity will review newly approved treatment approaches, their mechanisms of action, dosage/administration strategies, and safety profiles so that oncology/hematology nurses can make informed decisions, provide support for their patients, and devise strategies for side effect management and appropriate patient counseling.
- Activity Overview (5 min)
- Accurately Diagnosing Multiple Myeloma (5 min)
- Newly Approved Therapies: Rationale for Use and How They Work (20 min)
- Nursing Considerations for Newly Approved Therapies (15 min)
- Case Series: Managing Novel Agents (15 min)
This activity is intended for oncology nurses and advanced practice registered nurses.
At the conclusion of this activity, participants should be better able to:
- Outline revised diagnostic criteria to identify when and in which patients with multiple myeloma (MM) should treatment be initiated
- Assess efficacy and safety profiles supporting the use of newly approved agents for the treatment of relapsed/refractory MM
- Evaluate new agents under investigation in clinical trials for the treatment of MM
- Evaluate dosage and administration strategies of newly approved agents for the treatment of relapsed/refractory MM to select optimal treatment, provide appropriate care, and increase adherence
- Develop effective side effect management strategies associated with newly approved therapies for relapsed/refractory MM
Amy Pierre, BS, MSN, ANP-BC
|Niki Barkett, RN, BSN, OCN|
University of Arizona Cancer Center
Kathleen A. Colson, RN, BSN
Charise L. Gleason, MSN, ANP-C, AOCNP®
|Patricia A. Mangan, RN, MSN, APRN, BC|
Nurse Lead Hematologic Malignancies and Bone Marrow and Stem Cell Transplant Programs
Abramson Cancer Center
University of Pennsylvania College of Nursing
Tiffany Richards, MS, RN, ANP, AOCNP®
|Kristyn Romanowski, BSN, BS, RN|
Rocky Mountain Cancer Centers
Michelle Sapp, DNPP, ANP, BC
|Joseph D. Tariman, BSN, MA, ARNP-BC, OCN®, PhD|
Assistant Professor, Nursing
College of Science & Health
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.0 contact hour may be earned for successful completion of this activity.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13664, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 4 weeks.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Amy E. Pierre, B.S., MSN, APN-BC||Amy E. Pierre, B.S., MSN, APN-BC, reported a financial interest/relationship or affiliation in the form of ; Speakers' bureau, Amgen, Inc.|
|Niki Barkett, RN, BSN, OCN||Niki Barkett, RN, BSN, OCN, has no real or apparent conflicts of interest to report.|
|Kathleen A. Colson, BSN, RN||Kathleen A. Colson, RN, BSN, reported a financial interest/relationship or affiliation in the form of: Advisory board, Celgene Corp; Takeda Oncology|
Charise L. Gleason, MSN, ANP-C, AOCNP®
|Charise L. Gleason, MSN, ANP-C, AOCNP®, has no real or apparent conflicts of interest to report.|
|Patricia A. Mangan, MSN, RN, APRN, BC||Patricia A. Mangan, RN, MSN, APRN, BC, reported a financial interest/relationship or affiliation in the form of: Advisory board/consulting, Kik Pharmaceuticals; Speakers' bureau, Amgen, Inc, Celgene Corp, Takeda Oncology|
|Tiffany Richards, MS, RN, ANP, AOCNP®||Tiffany Richards, MS, RN, ANP, AOCNP®, reported a financial interest/relationship or affiliation in the form of: Consultant, Takeda Pharmaceuticals, Inc.; Onyx; and Celgene Corporation.|
|Kristyn Romanowski, BSN, BS, RN||Kristyn Romanowski, BSN, BS, RN, reported a financial interest/relationship or affiliation in the form of Advisory board, AbbVie, Janssen Pharmaceuticals, Inc; Speakers' bureau, Celgene Corp|
Michelle Sapp, DNPP, ANP, BC
|Michelle Sapp, DNPP, ANP, BC has no real or apparent conflicts of interest to report.|
|Joseph D. Tariman, PhD, MN, RN, ARNP-BC, OCN®||Joseph D. Tariman, BSN, MA, ARNP-BC, OCN®, PhD has no real or apparent conflicts of interest to report.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.
Charles E. Willis, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower consults for Pfizer, Inc; Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; and Jocelyn Timko hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by educational grants from Takeda Oncology and Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC.
There is no fee for this educational activity.
This activity is jointly provided by Annenberg Center for Health Sciences and AXIS Medical Education in collaboration with Postgraduate Institute for Medicine.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance